Home Featured Page 279

Featured

Latest

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Will the Biden Administration Embrace Federal Psychedelic Reform?

Center for Psychedelic Medicine Established at NYU Langone Health

So, You Want to Take Ibogaine: Here’s What You Need to...

Red Light Holland Announces Closing of $11.6 Million Bought Deal Financing

Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences

Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation...

NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase...

1...278279280...296 Page 279 of 296

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Interview With Christi Myers

Interview With Ronan Levy

Will the Biden Administration Embrace Federal Psychedelic Reform?

Center for Psychedelic Medicine Established at NYU Langone Health

So, You Want to Take Ibogaine: Here’s What You Need to...

Red Light Holland Announces Closing of $11.6 Million Bought Deal Financing

Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences

Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation...

NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase...

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY